06 Feb

Medical and Patient Groups Warn Congress Against “Right to Try”

Dozens of medical organizations and patient advocacy groups are pushing back against so-called “right-to-try” legislation that passed the Senate in August and is now under consideration in the House. An open letter sent today to House leaders is the latest opposition to the Republican-led push to give desperate patients access to experimental drugs without FDA oversight. President Donald Trump urged passage of a right-to-try bill in his State of the Union speech.

“Our organizations support patient access to unapproved therapies,” the letter reads, in part. “However, the right-to-try bills currently under consideration in the House do not effectuate policy changes that… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

06 Feb

CALL FOR PROPOSALS FOR ACTION GRANTS UNDER 2018 RIGHTS, EQUALITY AND CITIZENSHIP WORK PROGRAMME

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: REC-AG-2018Pillar: REC Programme 2014-2020Planned Opening Date: Deadline: Tue, 19 Jun 2018 17:00:00 (Brussels local time)Modification Date: Tue, 6 Feb 2018Latest information: The submission session is now available for: REC-RCIT-CITI-AG-2018(REC-AG)

05 Feb

2018 Farnborough Airshow – 16-22 July 2018, Farnborough Airport, United Kingdom

[Source: Research & Innovation] Farnborough Air show is one of the world’s most important air shows the and a real ‘place to be’ for the aviation community.
After the successful experience at Le Bourget 2017, RTD/transport and Clean Sky JU will participate with a joint stand gathering all the different EC services and actors involved in the aviation sector under the unique corporate EC banner.
More info coming soon…

05 Feb

Prothena Chief Medical Officer Sarah Noonberg Resigns

Prothena’s (NASDAQ: PRTA) chief medical officer, Sarah Noonberg, is stepping down from her post nine months after starting the job. Ireland-based Prothena, which has its U.S. operations in South San Francisco, CA, gave no reason for Noonberg’s departure other than to say that she decided to resign and will provide “transitional support” to the company through March 15.

While Prothena searches for Noonberg’s replacement, the company said retired chief medical officer Martin Koller will return temporarily on a consulting basis. Prothena’s lead drug, NEOD001, is in clinical testing as a potential treatment for AL amyloidosis, a rare disease… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

05 Feb

340B Drug Discount Program At-A-Glance

In 1992, with the support of the biopharmaceutical industry, Congress created the 340B Drug Discount Program to help uninsured and vulnerable patients gain access to affordable prescription drugs. Over the years, however, there have been growing signs that this program has expanded well past the intent of Congress and that patients may not be seeing the benefits they deserve.

Just last month, the House Energy and Commerce Committee published a review of 340B concluding that the program has grown far beyond its original scope, leading to growing problems with accountability and transparency. And building on these findings, a new study in the New England Journal of Medicine offered fresh evidence that 340B functions almost entirely as a source of revenue for hospitals, rather than as a benefit for vulnerable patients.

In our latest infographic, we dive into the current state of 340B, highlight areas that are in need of reform, and showcase expert viewpoints on the issue.

To view the full infographic, click here.

03 Feb

Comparing iShares NASDAQ Biotechnology Index (IBB) and Cannae (CNNE)

Cannae (NYSE: CNNE) and iShares NASDAQ Biotechnology Index (NASDAQ:IBB) are both finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations …

03 Feb

Arcturus Terminates CEO, Names Mark Herber as Interim President

Arcturus photo used with permission

Arcturus Therapeutics (NASDAQ: ARCT) said today it has fired co-founder and CEO Joseph E. Payne (on the right in above photo), and named Mark Herber, vice president of business development and alliance management, as interim president.

The San Diego-based early stage biotech, which specializes in RNA medicines, did not explain in a statement today why the Arcturus board decided to terminate Payne-only that his dismissal “is not related to Arcturus’ operational performance, ongoing programs, financial condition, or financial reporting.”

The unexpected announcement nevertheless sent the price of Arcturus shares spiraling in after-hours trading, falling by $1.38, nearly 19 percent, to… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

02 Feb

Call for projects on preventing and countering violent radicalisation

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: ISFP-2017-AG-RADPillar: Crisis and terrorismOpening Date: Deadline: Thu, 15 Mar 2018 17:00:00 (Brussels local time)Modification Date: Fri, 2 Feb 2018Latest information: Precision added in section 6.1 of the call textregarding the non-eligibility of the international organisations.

02 Feb

Super Bowel: GMOs Make for a Super Party Spread

In honor of the big game this Sunday, I thought we would look at how biotechnology, specifically GMOs, have benefited some of the foods that are sure to be part of many Super Bowl party spreads. Whether you’re rooting for the Philadelphia Eagles or the defending champion New England Patriots, we can all thank biotechnology for ensuring we’re not hungry come halftime.

Cheese

From nachos to queso dip to cheeseburgers, cheese will be a staple at most Super Bowl parties this weekend. And as we touched on briefly before the Thanksgiving holiday, we can thank GMOs for allowing us to indulge in this popular snack item:

While most people don’t think of GMOs when they think of cheese, much of our cheese is made using biotechnology. Enzymes known as “rennet” are a critical part of the cheesemaking process. Years ago, the only source of that rennet was the lining of calf stomachs; however, biotech stepped in to help make the cheesemaking process more humane. Researchers used biotechnology to create genetically modified (GM) bacterium and yeast cells to produce rennet, which in turn could be used in making cheese. Between 80 to 90 percent of hard cheese made in the U.S. is made using GM rennet!

Unless you plan on extracting rennin from the lining of a calf’s stomach, you’ll are relying on GMOs for that cheese board at your Super Bowl celebration.

Tortilla Chips

What pairs well with any queso dip? Chips. More specifically, tortilla chips. Party guests may claim they’re full by the end of the first quarter, but I guarantee they’ll continue munching on chips until the Lombardi trophy ceremony.

Of course, the main ingredient in tortilla chips is corn, which is one of the most common crops benefiting from biotechnology. To meet demand for the crop, farmers plant corn that has been genetically modified to be resistant to damaging insects and tolerant of commonly used herbicides.   What many people don’t know is that genetically modified corn can also be disease resistant. As noted in an article on Livestrong.com, this type of corn may actually be safer than non-GMO corn for human consumption:

Another benefit of GMO corn is described in an International Council for Science, ICSU, report cited by the “Public Library of Science-Biology.” Corn bioengineered to carry disease resistance genes from naturally resistant plants contain lower levels of mycotoxins, substances produced by fungi growing on insect-infested, non-GMO corn crops. Myxotoxins are potentially carcinogenic to humans.

Therefore, not only does biotechnology allow for higher yields of the crop, it also safeguards against cancer causing substances.

Hamburgers and Hotdogs

Cheese and chips are good for munching throughout the game, but your guests will start to grow hungry without some type of protein.

Whether you are serving hamburgers or hotdogs, the livestock that led to that burger patty or sausage link most likely fed on some type of GM crop. According to GMO Answers, more than two-thirds of GM corn and half of GM soybeans are used for livestock feed. And much like GM crops, GM animal feed does not pose any risks to a person’s health. Even so, if there are a few people at your viewing party who refuse to eat GM foods, you can assure them that the hamburgers and hotdogs are actually GMO free:

Over one hundred scientific studies have found no difference in the productive performance or health of livestock that have been fed genetically engineered feedstuffs, and they found no presence of genetically engineered DNA or proteins in the milk, meat or eggs from animals that have eaten genetically engineered feed.

So, whether you’re whipping up some Philly cheesesteaks, classic New England Franks & Beans or some simple chips and salsa, remember to thank biotechnology for that super party spread.

02 Feb

Surefire Medical Appoints Szela CEO, Chomas Shifts to CTO

Mary Szela has been named CEO and president of Denver-based Surefire Medical. Szela’s chief executive experience includes posts at Melinta Therapeutics (NASDAQ: MLNT) and later, Novelion Therapeutics (NASDAQ: NVLN). At Surefire, she succeeds James Chomas, the company’s founder and its chief executive since 2009. Chomas will move to a different role as chief technology and oncology strategy officer. Surefire develops medical devices used to administer cancer drugs.

UNDERWRITERS AND PARTNERS